Molecular Pathogenesis of Mantle Cell Lymphoma: New Perspectives and Challenges With Clinical Implications

Seminars in Hematology

Volumn 48, Issue 3, 2011, Pages 155-165

  Navarro, Alba ^a   Royo, Cristina ^a   Hernández, Luis ^a   Jares, Pedro ^a   Campo, Elías ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; WNT PROTEIN;

ARTICLE; CANCER GENETICS; CARCINOGENESIS; CCND1 GENE; CELL CYCLE; CELL SURVIVAL; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 14; DISEASE COURSE; DNA DAMAGE; GENE; GENE OVEREXPRESSION; GENE TARGETING; LEUKEMIA; MANTLE CELL LYMPHOMA; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

CYCLIN D1; HUMANS; LYMPHOMA, MANTLE-CELL;

EID: 79960508834     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2011.04.001     Document Type: Article

References (76)

1. Jares P., Colomer D., Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007, 7:750-762.
2. Jares P., Campo E. Advances in the understanding of mantle cell lymphoma. Br J Haematol 2008, 142:149-165.
3. Welzel N., Le T., Marculescu R., et al. Templated nucleotide addition and immunoglobulin JH-gene utilization in t(11;14) junctions: implications for the mechanism of translocation and the origin of mantle cell lymphoma. Cancer Res 2001, 61:1629-1636.
4. Kienle D., Krober A., Katzenberger T., et al. VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome. Blood 2003, 102:3003-3009.
5. Hadzidimitriou A., Agathagelidis A., Murray F., et al. Sequence-based evidence for antigen selection in mantle cell lymphoma: remarkable immunoglobulin gene repertoire biases, stereotyped antigen-binding sites and recurrent hypermutations in certain subsets. 51st American Society of Hematology Annual Meeting, New Orleans, LA 2009.
6. Orchard J., Garand R., Davis Z., et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood 2003, 101:4975-4981.
7. Camacho F.I., Algara P., Rodriguez A., et al. Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. Blood 2003, 101:4042-4046.
8. Kolar G.R., Mehta D., Pelayo R., Capra J.D. A novel human B cell subpopulation representing the initial germinal center population to express AID. Blood 2007, 109:2545-2552.
9. Chen R.W., Bemis L.T., Amato C.M., et al. Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma. Blood 2008, 112:822-829.
10. Jiang Q., Feng M.G., Mo Y.Y. Systematic validation of predicted microRNAs for cyclin D1. BMC Cancer 2009, 9:194.
11. Wiestner A., Tehrani M., Chiorazzi M., et al. Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. Blood 2007, 109:4599-4606.
12. Sander B., Flygare J., Porwit-MacDonald A., et al. Mantle cell lymphomas with low levels of cyclin D1 long mRNA transcripts are highly proliferative and can be discriminated by elevated cyclin A2 and cyclin B1. Int J Cancer 2005, 117:418-430.
13. Rosenwald A., Wright G., Wiestner A., et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003, 3:185-197.
14. Betticher D.C., Thatcher N., Altermatt H.J., Hoban P., Ryder W.D., Heighway J. Alternate splicing produces a novel cyclin D1 transcript. Oncogene 1995, 11:1005-1011.
15. Marzec M., Kasprzycka M., Lai R., et al. Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. Blood 2006, 108:1744-1750.
16. Klier M., Anastasov N., Hermann A., et al. Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2. Leukemia 2008, 22:2097-2105.
17. Aggarwal P., Vaites L.P., Kim J.K., et al. Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase. Cancer Cell 2010, 18:329-340.
18. Li Z., Jiao X., Wang C., et al. Alternative cyclin D1 splice forms differentially regulated DNA damage response. Cancer Res 2010, 70:8802-8811.
19. Quintanilla-Martinez L., Slotta-Huspenina J., Koch I., et al. Differential diagnosis of cyclin D2+ mantle cell lymphoma based on fluorescence in situ hybridization and quantitative real-time-PCR. Haematologica 2009, 94:1595-1598.
20. Salaverria I., Zettl A., Bea S., et al. Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. J Clin Oncol 2007, 25:1216-1222.
21. Gesk S., Klapper W., Martin-Subero J.I., et al. A chromosomal translocation in cyclin D1-negative/cyclin D2-positive mantle cell lymphoma fuses the CCND2 gene to the IGK locus. Blood 2006, 108:1109-1110.
22. Wlodarska I., Dierickx D., Vanhentenrijk V., et al. Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. Blood 2008, 111:5683-5690.
23. Herens C., Lambert F., Quintanilla-Martinez L., Bisig B., Deusings C., de Leval L. Cyclin D1-negative mantle cell lymphoma with cryptic t(12;14)(p13;q32) and cyclin D2 overexpression. Blood 2008, 111:1745-1746.
24. Mozos A., Royo C., Hartmann E., et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica 2009, 94:1555-1562.
25. Ek S., Dictor M., Jerkeman M., Jirstrom K., Borrebaeck C.A. Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood 2008, 111:800-805.
26. Wang X., Asplund A.C., Porwit A., et al. The subcellular Sox11 distribution pattern identifies subsets of mantle cell lymphoma: correlation to overall survival. Br J Haematol 2008, 143:248-252.
27. Chen Y.H., Gao J., Fan G., Peterson L.C. Nuclear expression of sox11 is highly associated with mantle cell lymphoma but is independent of t(11;14)(q13;q32) in non-mantle cell B-cell neoplasms. Mod Pathol 2010, 23:105-112.
28. Lecluse Y., Lebailly P., Roulland S., Gac A.C., Nadel B., Gauduchon P. t(11;14)-positive clones can persist over a long period of time in the peripheral blood of healthy individuals. Leukemia 2009, 23:1190-1193.
29. Christian B., Zhao W., Hamadani M., et al. Mantle cell lymphoma 12 years after allogeneic bone marrow transplantation occurring simultaneously in recipient and donor. J Clin Oncol 2010, 28:e629-e632.
30. Racke F., Simpson S., Christian B., Blum K., Hasserjian R., Zhao W. Evidence of long latency periods prior to development of mantle cell lymphoma. 52nd ASH Annual Meeting and Exposition. Orlando, FL December 4-7 2010.
31. Bea S., Campo E. Secondary genomic alterations in non-Hodgkin's lymphomas: tumor-specific profiles with impact on clinical behavior. Haematologica 2008, 93:641-645.
32. Bea S., Ribas M., Hernandez J.M., et al. Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood 1999, 93:4365-4374.
33. Rubio-Moscardo F., Climent J., Siebert R., et al. Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood 2005, 105:4445-4454.
34. Salaverria I., Espinet B., Carrio A., et al. Multiple recurrent chromosomal breakpoints in mantle cell lymphoma revealed by a combination of molecular cytogenetic techniques. Genes Chromosomes Cancer 2008, 47:1086-1097.
35. Kohlhammer H., Schwaenen C., Wessendorf S., et al. Genomic DNA-chip hybridization in t(11;14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions. Blood 2004, 104:795-801.
36. Nagel I., Szczepanowski M., Martin-Subero J.I., et al. Deregulation of the telomerase reverse transcriptase (TERT) gene by chromosomal translocations in B-cell malignancies. Blood 2010, 116:1317-1320.
37. Schraders M., Pfundt R., Straatman H.M., et al. Novel chromosomal imbalances in mantle cell lymphoma detected by genome-wide array-based comparative genomic hybridization. Blood 2005, 105:1686-1693.
38. Tagawa H., Karnan S., Suzuki R., et al. Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. Oncogene 2005, 24:1348-1358.
39. Thelander E.F., Ichimura K., Collins V.P., et al. Detailed assessment of copy number alterations revealing homozygous deletions in 1p and 13q in mantle cell lymphoma. Leuk Res 2006, 31:1219-1230.
40. Rinaldi A., Kwee I., Taborelli M., et al. Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol 2006, 132:303-316.
41. Vater I., Wagner F., Kreuz M., et al. GeneChip analyses point to novel pathogenetic mechanisms in mantle cell lymphoma. Br J Haematol 2009, 144:317-331.
42. Bea S., Salaverria I., Armengol L., et al. Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling. Blood 2009, 113:3059-3069.
43. Kawamata N., Ogawa S., Gueller S., et al. Identified hidden genomic changes in mantle cell lymphoma using high-resolution single nucleotide polymorphism genomic array. Exp Hematol 2009, 37:937-946.
44. Hartmann E.M., Campo E., Wright G., et al. Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. Blood 2010, 116:953-961.
45. Pinyol M., Bea S., Pla L., et al. Inactivation of RB1 in mantle-cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis. Blood 2007, 109:5422-5429.
46. Honma K., Tsuzuki S., Nakagawa M., et al. TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood 2009, 114:2467-2475.
47. Navarro A., Bea S., Fernandez V., et al. MicroRNA expression, chromosomal alterations, and immunoglobulin variable heavy chain hypermutations in mantle cell lymphomas. Cancer Res 2009, 69:7071-7078.
48. Psyrri A., Papageorgiou S., Liakata E., et al. Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma. Clin Cancer Res 2009, 15:5724-5732.
49. Bruce S., Leinonen R., Lindgren C.M., et al. Global analysis of uniparental disomy using high density genotyping arrays. J Med Genet 2005, 42:847-851.
50. Sharp A.J., Locke D.P., McGrath S.D., et al. Segmental duplications and copy-number variation in the human genome. Am J Hum Genet 2005, 77:78-88.
51. Stankiewicz P., Shaw C.J., Dapper J.D., et al. Genome architecture catalyzes nonrecurrent chromosomal rearrangements. Am J Hum Genet 2003, 72:1101-1116.
52. Kotake Y., Zeng Y., Xiong Y. DDB1-CUL4 and MLL1 mediate oncogene-induced p16INK4a activation. Cancer Res 2009, 69:1809-1814.
53. Aggarwal P., Lessie M.D., Lin D.I., et al. Nuclear accumulation of cyclin D1 during S phase inhibits Cul4-dependent Cdt1 proteolysis and triggers p53-dependent DNA rereplication. Genes Dev 2007, 21:2908-2922.
54. Hernandez L., Bea S., Pinyol M., et al. CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a/ARF locus. Cancer Res 2005, 65:2199-2206.
55. Camacho E., Hernandez L., Hernandez S., et al. ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances. Blood 2002, 99:238-244.
56. Rai R., Dai H., Multani A.S., et al. BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. Cancer Cell 2006, 10:145-157.
57. Perez-Galan P., Roue G., Villamor N., Montserrat E., Campo E., Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006, 107:257-264.
58. Bhat K.M., Setaluri V. Microtubule-associated proteins as targets in cancer chemotherapy. Clin Cancer Res 2007, 13:2849-2854.
59. Neben K., Ott G., Schweizer S., et al. Expression of centrosome-associated gene products is linked to tetraploidization in mantle cell lymphoma. Int J Cancer 2007, 120:1669-1677.
60. Rizzatti E.G., Falcao R.P., Panepucci R.A., et al. Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways. Br J Haematol 2005, 130:516-526.
61. Rudelius M., Pittaluga S., Nishizuka S., et al. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 2006, 108:1668-1676.
62. Dal C.J., Zancai P., Terrin L., et al. Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. Blood 2008, 111:5142-5151.
63. Peponi E., Drakos E., Reyes G., Leventaki V., Rassidakis G.Z., Medeiros L.J. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Am J Pathol 2006, 169:2171-2180.
64. Perez-Galan P., Mora-Jensen H., Weniger M.A., et al. Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. Blood 2010, 117:542-552.
65. Hess J., Herbrecht R., Romaguera J., et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009, 27:3822-3829.
66. Gelebart P., Anand M., Armanious H., et al. Constitutive activation of the Wnt canonical pathway in mantle cell lymphoma. Blood 2008, 112:5171-5179.
67. Ortega-Paino E., Fransson J., Ek S., Borrebaeck C.A. Functionally associated targets in mantle cell lymphoma as defined by DNA microarrays and RNA interference. Blood 2008, 111:1617-1624.
68. Zhao J.J., Lin J., Lwin T., et al. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood 2010, 115:2630-2639.
69. Di L.L., Gomez-Lopez G., Sanchez-Beato M., et al. Mantle cell lymphoma: transcriptional regulation by microRNAs. Leukemia 2010, 24:1335-1342.
70. Mu P., Han Y.C., Betel D., et al. Genetic dissection of the miR-17~92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev 2009, 23:2806-2811.
71. Cloonan N., Brown M.K., Steptoe A.L., et al. The miR-17-5p microRNA is a key regulator of the G1/S phase cell cycle transition. Genome Biol 2008, 9:R127.1-R127.4.
72. Angelopoulou M.K., Siakantariz M.P., Vassilakopoulos T.P., et al. The splenic form of mantle cell lymphoma. Eur J Haematol 2002, 68:12-21.
73. Martin P., Chadburn A., Christos P., et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009, 27:1209-1213.
74. Eve H.E., Furtado M.V., Hamon M.D., Rule S.A. Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma. J Clin Oncol 2009, 27:e189-e190.
75. Fernandez V., Salamero O., Espinet B., et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 2010, 70:1408-1418.
76. Fusco A., Fedele M. Roles of HMGA proteins in cancer. Nat Rev Cancer 2007, 7:899-910.